Drugs / 68Ga-NB381
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06385652 | Apr 2024 → Jun 2025 overdue | plasma cell myeloma | Peking University First Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NB381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385652 ↗ |
| Known as | NB381 | “ultimately producing the CD38-targeted nuclear medicine small molecule diagnostic and therapeutic agent-68Ga-labeled nanobody NB381.” NCT06385652 ↗ |
| Modality | Protein / enzyme biologic | “This project uses a nanobody with high affinity for CD38 as the targeting moiety for the radiopharmaceutical” NCT06385652 ↗ |
| Route | Intravenous | “will be intravenously injected with prepared and quality-controlled 68Ga-NB381 (0.05-0.1 mCi/kg)” NCT06385652 ↗ |
| Target | CD38 | “high affinity and targets CD38” NCT06385652 ↗ |